Blood:NFE2突变可促进AML特异性遗传突变的获得

2019-03-20 不详 MedSci原创

中心点:AML患者的转录因子NFE2常发生突变。在小鼠中,NFE2突变可诱导MPN,随后转化成AML,并获得AML特异性的遗传变异。摘要:在急性髓系白血病(AML)中,获得性遗传变异具有预后意义,并可指导治疗决策的制定。目前临床算法已纳入了新发突变。Jonas Samuel Jutzi等人发现AML患者和髓肉瘤患者携带转录因子NFE2突变,并对其功能特征进行研究。研究人员既往在骨髓增殖性肿瘤患者中

中心点:

AML患者的转录因子NFE2常发生突变。

在小鼠中,NFE2突变可诱导MPN,随后转化成AML,并获得AML特异性的遗传变异。

摘要:

在急性髓系白血病(AML)中,获得性遗传变异具有预后意义,并可指导治疗决策的制定。目前临床算法已纳入了新发突变。

Jonas Samuel Jutzi等人发现AML患者和髓肉瘤患者携带转录因子NFE2突变,并对其功能特征进行研究。研究人员既往在骨髓增殖性肿瘤患者中发现NFE2突变,并证实NFE2突变可使小鼠出现骨髓及髓外异常增殖的表型。

现研究人员进一步发现34%的NFE2突变小鼠的表型进展成了白血病,伴有或不伴有脊髓肉瘤,或发展为孤立的脊髓肉瘤。而且这些脊髓肉瘤和白血病均发生了AML特异性的变异,包括8号染色体三体、5q上AML常见缺失片段的丢失以及肿瘤抑制因子Trp53突变。

本数据提示NFE2突变具有获得促进向髓肉瘤和/或AML发展的继发突变的倾向。

原始出处:

Jonas Samuel Jutzi, et al.Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.Blood 2019 :blood-2018-09-875047; doi: https://doi.org/10.1182/blood-2018-09-875047

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747840, encodeId=ab2e1e4784039, content=<a href='/topic/show?id=e7e095194c3' target=_blank style='color:#2F92EE;'>#遗传突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95194, encryptionId=e7e095194c3, topicName=遗传突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f11d35955911, createdName=sunyl19, createdTime=Thu Mar 05 10:30:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077534, encodeId=a52620e753441, content=<a href='/topic/show?id=3fc712e46cf' target=_blank style='color:#2F92EE;'>#NFE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12746, encryptionId=3fc712e46cf, topicName=NFE2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Tue Oct 22 18:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899284, encodeId=53e418992845a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Oct 21 08:30:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363306, encodeId=9ae036330682, content=向挑战病魔的科研人员致敬!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Thu Mar 21 10:59:31 CST 2019, time=2019-03-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747840, encodeId=ab2e1e4784039, content=<a href='/topic/show?id=e7e095194c3' target=_blank style='color:#2F92EE;'>#遗传突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95194, encryptionId=e7e095194c3, topicName=遗传突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f11d35955911, createdName=sunyl19, createdTime=Thu Mar 05 10:30:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077534, encodeId=a52620e753441, content=<a href='/topic/show?id=3fc712e46cf' target=_blank style='color:#2F92EE;'>#NFE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12746, encryptionId=3fc712e46cf, topicName=NFE2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Tue Oct 22 18:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899284, encodeId=53e418992845a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Oct 21 08:30:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363306, encodeId=9ae036330682, content=向挑战病魔的科研人员致敬!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Thu Mar 21 10:59:31 CST 2019, time=2019-03-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747840, encodeId=ab2e1e4784039, content=<a href='/topic/show?id=e7e095194c3' target=_blank style='color:#2F92EE;'>#遗传突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95194, encryptionId=e7e095194c3, topicName=遗传突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f11d35955911, createdName=sunyl19, createdTime=Thu Mar 05 10:30:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077534, encodeId=a52620e753441, content=<a href='/topic/show?id=3fc712e46cf' target=_blank style='color:#2F92EE;'>#NFE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12746, encryptionId=3fc712e46cf, topicName=NFE2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Tue Oct 22 18:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899284, encodeId=53e418992845a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Oct 21 08:30:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363306, encodeId=9ae036330682, content=向挑战病魔的科研人员致敬!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Thu Mar 21 10:59:31 CST 2019, time=2019-03-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747840, encodeId=ab2e1e4784039, content=<a href='/topic/show?id=e7e095194c3' target=_blank style='color:#2F92EE;'>#遗传突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95194, encryptionId=e7e095194c3, topicName=遗传突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f11d35955911, createdName=sunyl19, createdTime=Thu Mar 05 10:30:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077534, encodeId=a52620e753441, content=<a href='/topic/show?id=3fc712e46cf' target=_blank style='color:#2F92EE;'>#NFE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12746, encryptionId=3fc712e46cf, topicName=NFE2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Tue Oct 22 18:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899284, encodeId=53e418992845a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Oct 21 08:30:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363306, encodeId=9ae036330682, content=向挑战病魔的科研人员致敬!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Thu Mar 21 10:59:31 CST 2019, time=2019-03-21, status=1, ipAttribution=)]
    2019-03-21 坚强007

    向挑战病魔的科研人员致敬!!!

    0

相关资讯

Diabetes:NFE2诱导的miR-423-5p促进糖异生和高血糖!

由此可见,在肥胖状态下,肝脏NFE2/miR-423-5p轴的激活在2型糖尿病和非酒精性脂肪性肝病进展中发挥着重要作用,通过抑制FAM3A-ATP-Akt信号通路。

Blood:调控骨髓增生性肿瘤过表达NFE2的两种新型表观遗传通路

中心点:骨髓增生性肿瘤过表达NFE2与JAK2V617F介导的H3Y41磷酸化相关。JMJD1C是NFE2的靶基因,通过正反馈环促进骨髓增生性肿瘤过表达NFE2。摘要:转录因子NFE2在大多数骨髓增生性肿瘤(MPN)患者中过度表达。在免疫模式动物中,NFE2水平升高可导致自发性白血病转化的MPN表型。但是,导致NFE2过表达的分子机制及其下游靶点尚未详细了解。近日,Blood上发表一篇相关文献。研